Profil bibliographique

José Miguel Valera

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

15Publications signalées

369Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Liver Diseases and ImmunityLiver physiology and pathologyDrug Transport and Resistance MechanismsCeliac Disease Research and ManagementPediatric Hepatobiliary Diseases and Treatments

Publications récentes

Accès ouvert 2026 articleOpenAlex

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial

Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Ulus Salih Akarca et autres

0 citationsJournal of Hepatology

Accès ouvert 2026 conference-abstractOpenAlex

P55 Long-term elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis (PBC)

Amandeep Phagura, Cynthia Levy, Ulus Akarca, Mario Reis Alvares-da-Silva et autres

0 citationsE-Posters

2026 articleOpenAlex

138 - LONG-TERM TREATMENT WITH ELAFIBRANOR LEADS TO BIOCHEMICAL AND SYMPTOMATIC IMPROVEMENTS FOR AT LEAST 3 YEARS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS

Antonio Olveira, Cynthia Levy, Ulus Salih Akarca, Mario Reis Alvares-da-Silva et autres

0 citationsGastroenterología y Hepatología

2025 conference-paperOpenAlex

Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years

Kris V. Kowdley, Christopher L. Bowlus, C Levy, Ulus Salih Akarca et autres

1 citationZeitschrift für Gastroenterologie

2025 conference-abstractOpenAlex

P199 Long-term efficacy and safety of elafibranor in primary biliary cholangitis: interim results from the open-label extension of the ELATIVE® trial

Áine M. Prendergast, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy et autres

0 citations

2024 conference-abstractOpenAlex

P23 Efficacy of elafibranor in primary biliary cholangitis: results from the variable double-blind period of ELATIVE®, a randomised, placebo-controlled phase III trial

Christopher L. Bowlus, Kris V. Kowdley, Cynthia Levy, Ulus Salih Akarca et autres

0 citations

2024 conference-abstractOpenAlex

LBP-006 Efficacy of elafibranor in primary biliary cholangitis: results from the variable double-blind period of ELATIVE®, a randomised, placebo-controlled phase III trial

Christopher L. Bowlus, Kris V. Kowdley, Cynthia Levy, Ulus Salih Akarca et autres

0 citationsJournal of Hepatology

2023 articleOpenAlex

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Ulus Salih Akarca et autres

294 citationsNew England Journal of Medicine

2014 articleOpenAlex

Estilos de Apego y Agresividad en Adolescentes

Marián Brando, José Miguel Valera, Yubiza Zárate

11 citationsRevista Psicología

2010 articleOpenAlex

Regresión histológica de la fibrosis hepática con tratamiento inmunosupresor en hepatitis autoinmune

José Miguel Valera, G Smok, Sylvia Márquez, Jaime Poníachik et autres

10 citationsGastroenterología y Hepatología

2008 articleOpenAlex

Estudio de enfermedad celíaca en pacientes con enfermedad por hígado graso no alcohólico y con hepatopatías autoinmunes

José Miguel Valera, Carmen Hurtado, Jaime Poníachik, P Abumohor et autres

6 citationsGastroenterología y Hepatología

2007 articleOpenAlex

Oral Ulcers Produced by Mycophenolate Mofetil in Two Liver Transplant Patients

Javier Rubén León Naranjo, Jaime Poníachik, D. Cisco, Jorge Contreras et autres

33 citationsTransplantation Proceedings

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.